000			03027nam a22003735i 4500
999			_c116784 _d116784
001			116784
003			ES-MaUEC
005			20230216105650.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190617s2019 gw | s |||| 0|eng d
020			_a9783319566375
024	7		_a10.1007/978-3-319-56637-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS420 _b2019 EB
245	0	0	_aDrug Discovery and Evaluation : _bMethods in Clinical Pharmacology _cedited by Franz J. Hock, Michael R. Gralinski.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2019
300			_b1 recurso en línea
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	0		_aBiomedical and Life Sciences (Springer-11642)
520	3		_aDDrug Discovery and Evaluation has become a more and more difficult, expensive and time-consuming process. The effect of a new compound has to be detected by in vitro and in vivo methods of pharmacology. The activity spectrum and the potency compared to existing drugs have to be determined. As these processes can be divided up stepwise we have designed a book series "Drug Discovery and Evaluation" in the form of a recommendation document. The methods to detect drug targets are described in the first volume of this series "Pharmacological Assays" comprising classical methods as well as new technologies. Before going to man, the most suitable compound has to be selected by pharmacokinetic studies and experiments in toxicology. These preclinical methods are described in the second volume "Safety and Pharmacokinetic Assays". Only then are first studies in human beings allowed. Special rules are established for Phase I studies. Clinical pharmacokinetics are performed in parallel with human studies on tolerability and therapeutic effects. Special studies according to various populations and different therapeutic indications are necessary. These items are covered in the third volume: "Methods in Clinical Pharmacology". For the 2nd edition, all the existing chapters will be revised and completely updated. A large number of assays were added. New chapters were included, such as pain, addiction, gene therapy, orphan diseases etc. etc. The complete work was new arranged.
650		7	_2embne _9395061 _aMedicamentos _xDiseño
650		7	_2embne _aQuímica farmacéutica _9141808
700			_aHock, Franz Jakob _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _985329
700	1		_aGralinski, Michael R _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
773	0		_tSpringer Nature Living Reference
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-56637-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_BiomedLife_2019
998			_aSI _cm _dz _feng _ggw _h0 _b01/2020 _ek _zSI